---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-021541"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2026-03-27T23:59:59+00:00"
generated_at: "2026-05-15T08:34:47.482557+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Ocugen furnishes investor presentation; no material new details available from filing

## Summary
- Exhibit 99.1 presentation attached to 8-K but full content not provided in the filing excerpt.
- Ocugen (OCGN) continues to highlight gene therapy pipeline; no financial or clinical updates disclosed.
- Presentation posted on company website for investor use; no specific new events or numbers reported.

## SEC filing metadata
- accession: 0001628280-26-021541
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2026-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000162828026021541/0001628280-26-021541-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000162828026021541/ocgn-20260326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-021541
- JSON: https://secwatch.observer/filing/0001628280-26-021541.json
- Plain text: https://secwatch.observer/filing/0001628280-26-021541.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.